Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors

被引：100
|
作者：
Kwekkeboom, Dik J. [1 ]
Krenning, Eric P. [1 ]
机构：
[1] Univ Med Ctr, Erasmus MC, Dept Nucl Med, NL-3015 CE Rotterdam, Netherlands
来源：
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2016年 / 30卷 / 01期
关键词：
Neuroendocrine tumor; Carcinoid; Radionuclide therapy; PRRT; Treatment; RADIOLABELED SOMATOSTATIN ANALOG; PHASE-I; RADIOPEPTIDE LU-177-OCTREOTATE; CARCINOID-SYNDROME; SALVAGE THERAPY; COMBINATION; TOXICITY; SURVIVAL; Y-90-DOTATOC; CAPECITABINE;
D O I：
10.1016/j.hoc.2015.09.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Peptide receptor radionuclide therapy (PRRT) is a promising new treatment modality for inoperable or metastasized gastroenteropancreatic neuroendocrine tumors patients. Most studies report objective response rates in 15% to 35% of patients. Progression-free (PFS) and overall survival (OS) compare favorably with that for somatostatin analogues, chemotherapy, or newer, "targeted" therapies. Prospective, randomized data regarding the potential PFS and OS benefit of PRRT compared with standard therapies is anticipated.
引用
收藏
页码：179 / +
页数：15
相关论文
共 50 条
  • [21] Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors
    Ramage, John
    Naraev, Boris G.
    Halfdanarson, Thorvardur R.
    SEMINARS IN ONCOLOGY, 2018, 45 (04) : 236 - 248
  • [22] Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?
    Hope, Thomas A.
    Pavel, Marianne
    Bergsland, Emily K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (24) : 2818 - +
  • [23] Peptide Receptor Radionuclide Therapy versus Capecitabine/Temozolomide for the Treatment of Metastatic Pancreatic Neuroendocrine Tumors
    Gujarathi, Rushabh
    Tobias, Joseph
    Abou Azar, Sara
    Keutgen, Xavier M.
    Liao, Chih-Yi
    CANCERS, 2024, 16 (17)
  • [24] Peptide receptor radionuclide therapy versus capecitabine/ temozolomide for the treatment of metastatic pancreatic neuroendocrine tumors
    Gujarathi, R.
    Tobias, J.
    Azar, S. A.
    Keutgen, X.
    Liao, C-Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S94 - S94
  • [25] Value of Peptide Receptor Radionuclide Therapy as Neoadjuvant Treatment in the Management of Primary Inoperable Neuroendocrine Tumors
    Opalinska, Marta
    Sowa-Staszczak, Anna
    Grochowska, Anna
    Olearska, Helena
    Hubalewska-Dydejczyk, Alicja
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [26] Addendum to the Editorial "Joint Guidance on Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors"
    Delbeke, Dominique
    Graham, Michael M.
    JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (07) : 1170 - 1170
  • [27] The role of peptide receptor radionuclide therapy in advanced/metastatic thoracic neuroendocrine tumors
    Bodei, Lisa
    Cwikla, Jaroslaw B.
    Kidd, Mark
    Modlin, Irvin M.
    JOURNAL OF THORACIC DISEASE, 2017, 9 : S1511 - S1523
  • [28] Tumor Cystic Necrosis Following Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors
    Ladwa, Rahul
    Wen Hong, Hooi
    Wyld, David
    Pattison, David A.
    Burge, Matthew
    CLINICAL NUCLEAR MEDICINE, 2018, 43 (03) : 186 - 187
  • [29] Peptide receptor radionuclide therapy and theranostics beyond neuroendocrine tumors and into the next decade
    Satz, S.
    Baum, R. P.
    Sathekge, M. M.
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56
  • [30] Quality Of Life in Patients with Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy
    Wang, Q.
    Librizzi, D.
    Bagheri, S.
    Ebrahimifard, A.
    Luster, M.
    Yousefi, B. H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S246 - S247
12345